1 / 11

Aarkstore - Complete 2013-14 Induced Pluripotent Stem Cell (

Stem cell research and experimentation has been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types.

addyparker2350
Télécharger la présentation

Aarkstore - Complete 2013-14 Induced Pluripotent Stem Cell (

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Healthcare Complete 2013-14 Induced Pluripotent Stem Cell (iPSC) Industry Report Browse Complete Report - http://www.aarkstore.com/healthcare/51108/Complete-2013-14-Induced-Pluripotent-Stem-Cell-iPSC-Industry-Report f

  2. f Executive Summary Stem cell research and experimentation has been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have caused great commercial interest, with potential applications ranging from the use of stem cells in reversal or treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Diseases such as Huntington’s Chorea, Parkinson’s Disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage. Traditionally, scientists have worked with both embryonic and adult stem cells as research tools. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral and spiritual controversy surrounding their use for research purposes. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which creates narrow options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics.

  3. f Executive Summary Discovery:Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSC). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells at Kyoto University in Japan was the first instance in which there was successful generation of the iPSC. In 2007, a series of follow-up experiments were done at Kyoto University in which human adult cells were transformed into iPSC cells.While there has been continued excitement at the prospect of what such artificially re-manufactured cells could contribute to medical advances, there have also been issues along the way. By 2010, there were a number of private companies that were ready to capitalize on the breakthrough technology that iPSCs represent. One such company, Advanced Cell Technology in Worcester, Massachusetts, discovered several problematic issues while conducting experiments for the purpose of applying for U.S. Food and Drug Administration approval to use iPSCs in therapeutic applications. Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced.

  4. f Executive Summary Furthermore, the past twelve months have been a time of massive change for the industry. 2013 was the first year in which clinical research involving transplant of iPSCs into humans was initiated, with Masayo Takahashi of the RIKEN Center in Japan investigating the safety of iPSC-derived cell sheets in patients with macular degeneration. In another landmark event, Cellular Dynamics International (CDI) went public in July 2013 with a offering that raised $43 million dollars for the company, securing the companys position as the global leader in producing high-quality human iPSCs and differentiated cells in industrial quantities. In March of 2013, Celullar Dynamics International and the Coriell Institute for Medical Research announced receiving multi-million dollars grants from the California Institute for Regenerative Medicine (CIRM) for the creation of iPSC lines from 3,000 healthy and diseased donors, a result that will create the world’s largest human iPSC bank.2013 represents a major year for advances in clinical research applications, production and differentiation technologies, and biobanking of iPSCs. It is clear that iPSCs are a vital research trend within the scientific community.

  5. Table of Content ABSTRACTII. BACKGROUNDA. DefinitionB. DiscoveryC. Advantages & DisadvantagesIII. TIMELINEA. Production of iPSCs (Key Events)B. Full Timeline of EventsIV. RESEARCH APPLICATIONSA. Pharmaco-Toxicological ScreeningB. Disease ModelingC. Autologous Cell TransplantationD. Breakdown of iPSC Research, By Applied Research Application

  6. f Table of Content V. CHARACTERIZATION OF iPSC RESEARCH ADVANCESA. Methods of Making iPSCs – Comparison of Methods by Downstream ApplicationB. Summary of iPSC Derivation Methods, by Cell TypeC. Diseases in Which iSPCs Have Been Derived from PatientsVI. COMPANIES SELLING iPSC RESEARCH PRODUCTSA. Complete List of CompaniesB. Rate of Entrants by YearVII. TYPES OF iPSC RESEARCH PRODUCTSA. Stem Cell Product CategoriesB. iPSC Market Share Breakdown, By Product Area

  7. f Table of Content VIII. COMPANIES DEVELOPING iPSC THERAPIESA. Commerical Entities1. Cellular Dynamics International (CDI)2. Fate Therapeutic3. iPerian 4. ViaCyte 5. Advanced Cell Technology (ACT) B. Non-Commercial Organizations Developing iPSC TherapiesIX. STRATEGIC COLLABORATIONS FOR DEVELOPMENT OF iPSC PRODUCTSA. Life Technologies (Recently Acquired by Thermo Fisher Scientific)B. Lonza Group AGC. EMD MilliporeD. Sigma AldrichE. Roslin Cells, Ltd.F. ArunA BiomedicalG. CeeTox and Cellular Dynamics

  8. f Table of Content X. MARKET TREND ANALYSISA. Clinical TrialsB. Grant Analysis1. Historical Analysis2. Future 5-Year ProjectionC. Patent AnalysisD. Scientific Publication Analysis1. Historical Data 2. Future 5-Year Projections3. Comparison of iPSC Research Frequency, Relative to Other Cell TypesE. Search Phrase Analysis1. Google News Search Results for iPSC Terms2. iPSC Product Launches, by YearF. Geographical Analysis: Domestic vs. International Status1. Number of iPSC Labs, by Region of World 2. Percent of Total iPSC-Specific Research Funding, by Region of WorldG. Additional Sources of iPSC Research Funding 

  9. f Related Reports Epilepsy Market in the US 2015-2019 Global Ankylosing Spondylitis Market 2015-2019 Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Global High-performance Thermoplastics Market 2015-2019 Global Anxiety Disorders Market 2015-2019 Global Breast Imaging Market 2015-2019 Global Cancer Biomarkers Market 2015-2019 Global Fluid Treatment Market 2015-2019 Global Rapid Prototyping Equipment Market 2015-2019 Healthcare RCM Outsourcing Market in the US 2015-2019 Medical Technologies Market in the APAC Region 2015-2019 Healthcare Market Research Reports

  10. f Complete 2013-14 Induced Pluripotent Stem Cell (iPSC) Industry Report Published: Feb 2014 | 127 Pages Stem cell research and experimentation has been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. Price

  11. f Contact Us You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news Office Aarkstore Enterprise Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 Partners contact: 022-27564953

More Related